Paysign, Inc. (NASDAQ:PAYS) CEO Sells $34,200.00 in Stock

Paysign, Inc. (NASDAQ:PAYS) CEO Mark Newcomer sold 12,000 shares of the firm’s stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $2.85, for a total transaction of $34,200.00. Following the completion of the sale, the chief executive officer now owns 9,036,886 shares of the company’s stock, valued at $25,755,125.10. This trade represents a 0.13 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Mark Newcomer also recently made the following trade(s):

• On Tuesday, January 21st, Mark Newcomer sold 61,000 shares of Paysign stock. The stock was sold at an average price of $2.89, for a total transaction of $176,290.00.
• On Monday, December 9th, Mark Newcomer sold 41,000 shares of Paysign stock. The stock was sold at an average price of $3.31, for a total value of $135,710.00.
• On Wednesday, November 20th, Mark Newcomer sold 25,000 shares of Paysign stock. The shares were sold at an average price of $3.27, for a total value of $81,750.00.
• On Monday, November 18th, Mark Newcomer sold 40,000 shares of Paysign stock. The stock was sold at an average price of $3.24, for a total value of $129,600.00.

Paysign Stock Performance

PAYS opened at $2.87 on Friday. The company has a market cap of $153.69 million, a price-to-earnings ratio of 19.13 and a beta of 0.95. Paysign, Inc. has a one year low of $2.70 and a one year high of $5.59. The business’s fifty day moving average is $3.13 and its two-hundred day moving average is $3.89.

Paysign (NASDAQ:PAYS) last released its quarterly earnings data on Tuesday, November 5th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of $0.01 by $0.02. Paysign had a net margin of 14.28% and a return on equity of 30.64%. The business had revenue of $15.26 million for the quarter, compared to analyst estimates of $14.96 million. During the same period in the previous year, the firm earned $0.02 EPS. On average, analysts predict that Paysign, Inc. will post 0.21 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on PAYS. Lake Street Capital began coverage on shares of Paysign in a research report on Friday, December 20th. They set a “buy” rating and a $6.00 target price on the stock. Barrington Research reissued an “outperform” rating and set a $7.00 price objective on shares of Paysign in a report on Monday, November 4th.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of PAYS. Renaissance Technologies LLC lifted its stake in Paysign by 25.0% in the 2nd quarter. Renaissance Technologies LLC now owns 1,504,380 shares of the company’s stock valued at $6,484,000 after buying an additional 301,000 shares in the last quarter. Joule Financial LLC purchased a new stake in shares of Paysign in the third quarter valued at $1,478,000. Royce & Associates LP acquired a new stake in shares of Paysign during the third quarter valued at $814,000. Sanctuary Advisors LLC increased its position in Paysign by 4.3% during the 3rd quarter. Sanctuary Advisors LLC now owns 121,089 shares of the company’s stock worth $419,000 after purchasing an additional 5,000 shares in the last quarter. Finally, GSA Capital Partners LLP raised its stake in Paysign by 31.2% in the 3rd quarter. GSA Capital Partners LLP now owns 117,028 shares of the company’s stock valued at $429,000 after purchasing an additional 27,829 shares during the last quarter. 25.89% of the stock is owned by hedge funds and other institutional investors.

Paysign Company Profile

Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.